Arrhythmia and Myocardial Infarction

In a fascinating discovery published in the journal Science, researchers have uncovered a new reason why a heart attack can lead to a dangerous heart rhythm, or ventricular tachycardia. The study found that a protein called resistin-like molecule-γ (RELMγ), secreted by immune cells called neutrophils, may be a key culprit.

The Heart Attack and the "Misfiring" Protein

Normally, neutrophils are a crucial part of our immune system, fighting off bacteria by punching holes in their membranes. However, after a heart attack, these cells rush to the injured heart tissue. The new research suggests that in this environment, the neutrophils' defense mechanism "misfires," and they release RELMγ, which attacks and perforates the membranes of heart muscle cells.

This membrane damage disrupts the heart cells' electrical activity, creating a state of instability that can trigger life-threatening ventricular tachycardia. The study, conducted in mice and human heart tissue, found that by removing this protein from the neutrophils in mice, the occurrence of this dangerous arrhythmia was significantly reduced.




Ventricular Tachycardia – Monomorphic VT


Why This is a Big Deal

This discovery offers a novel explanation for post-heart attack arrhythmias and opens the door for a completely new approach to treatment. Instead of just managing the heart rhythm, future therapies could focus on blocking the action of RELMγ to prevent the arrhythmia from happening in the first place.

This research highlights the complex link between the immune system and heart disease, and it could lead to new drugs that save lives by preventing sudden cardiac death after a heart attack.

To know more visit: https://www.cardiology.scientexconference.com/

Comments

Post a Comment

Popular posts from this blog

Image
  Ventricular Assist Device – Miniature The treatment of individuals with severe heart failure has been transformed by the development of a ventricular assist device (VAD). When a donor heart cannot be identified, the VAD, which was initially designed as a bridge to transplantation , has been proved to extend life and improve quality of life. Older models needed patients to ambulate with hefty , huge external batteries and control devices and required the implantation of a big pump. Yet in the upcoming years, a number of ground-breaking advancements in device size , battery life, and even wireless charging technologies may render these devices physically undetectable and possibly reduce patient vulnerability to infections. The rates of haemolysis, thrombosis, and secondary aortic valve insufficiency have also been constrained by numerous mechanical improvements and newer operating paradigms. Cardiac Decellularization and Engineered Heart Tissue Promising new direction...
Read more
Image
Myocardial infarction events involving morality, incredibly high temperatures, and minute particles.  Myocardial infarction (MI) morbidity has been connected to extreme temperature events (ETEs), such as heat wave and cold spell, but their effects on MI mortality are less well understood. Although ambient fine particulate matter (PM2.5) and severe temperatures may work in concert to increase cardiovascular mortality , it is still unclear whether or how ETEs and PM2.5 interact to cause MI deaths.METHODS: To examine the relationship between exposure to ETEs and PM2.5 and MI mortality and assess their interacting effects, a time-stratified case-crossover study of 202 678 MI deaths in Jiangsu province, China, from 2015 to 2020 was conducted. Twelve ETE definitions were created using a variety of temperature thresholds and durations based on the perceived ambient temperature. In order to estimate daily ETEs and PM2.5exposures , values were taken from validated grid datasets at reside...
Read more

New Drug Nearly Eradicates “Stealth” Cholesterol (Lp(a)) – A Game‑Changer in Heart Disease Prevention

Image
A recent clinical trial reported in the New England Journal of Medicine and showcased at the American College of Cardiology revealed that lepodisiran—an experimental RNA-targeting drug—can reduce lipoprotein(a) [Lp(a)] by nearly 100% after a single dose, with sustained effects over a year 🔍 What You Need to Know Lp(a) is a genetically determined, stealth cholesterol that significantly raises the risk of heart attacks and strokes yet is not addressed by diet or standard statins. The Phase 2 trial, involving 320 participants across 10 countries, showed almost total Lp(a) suppression at 6 months, maintained at 1 year. Reported side effects were mild, primarily limited to injection-site reactions. No serious safety issues were found.                      🌍 Why This Matters This breakthrough could pave the way for targeted Lp(a) therapies—potentially reducing cardiovascular risk in over 1.4 billion people globally with elevated levels....
Read more